# A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric Cancer

> **NCT00952497** · PHASE2 · COMPLETED · sponsor: **ACT Biotech, Inc** · enrollment: 48 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Cisplatin, Capecitabine, Telatinib

## Key facts

- **NCT ID:** NCT00952497
- **Lead sponsor:** ACT Biotech, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2011-10
- **Final completion:** 2012-01
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2012-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00952497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00952497, "A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00952497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*